ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Efficacy of Primaquine for the Radical Cure of Plasmodium vivax Malaria in Northeast Myanmar and the Impact of Cytochrome P450 2D6 Genotypes.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Rising burden of Plasmodium vivax in Mizoram: an emerging threat to malaria elimination in Northeast India.BMC infectious diseases · 2026Article
- The evolving landscape of pharmacogenomics: Current achievements and future directions.Pharmacological reviews · 2026Review
- Reduced cytochrome P-450 (CYP) 2D6 activity and Plasmodium vivax malaria risk in Amazonians: A retrospective, population-based cohort study.PLoS neglected tropical diseases · 2026Article
- Radical Cure of Plasmodium vivax With Primaquine and CYP2D6 Polymorphism in Southeast Asia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
backgroundThe antirelapse activity of primaquine (PQ) for Plasmodium vivax malaria depends on the host cytochrome P450 2D6 (CYP2D6) enzyme activity. This study aimed to assess the efficacy of PQ for the radical cure of P. vivax malaria in the Greater Mekong Subregion and determine the association of the post-PQ recurrences with CYP2D6 genotypes.
methodsIn 2014-2017, a total of 239 patients with uncomplicated P. vivax malaria in northeastern Myanmar were prospectively enrolled to receive a standard regimen of 3-day chloroquine and 14-day low-dose PQ (total dose, 3.5 mg/kg) as directly observed therapy. Patients were followed up biweekly for 1 year. A nested case-control study was designed to compare 49 patients with P. vivax malaria recurrences and 49 without recurrence. The CYP2D6 genotype-predicted activity score (AS) was used to estimate the unadjusted odds ratio of recurrence.
resultsDuring the 1-year follow-up, 54 recurrences were recorded with 65% occurring within 6 months after PQ treatment. The cumulative risk of recurrence was 17.3% (95% confidence interval, 11.9%-22.7%) at 6 months and 25.6% (19.3%-31.9%) at 1 year. Most recurrences were asymptomatic, with reduced parasitemia and gametocytemia. The CYP2D6*36+*10 tandem type with decreased function was the most prevalent allele (34.7%). Patients with an AS ≤1.25 had a significantly higher risk of recurrence (odds ratio, 6.53 [95% confidence interval, 2.0-21]; P < .001).
conclusionsMore than 75% of patients with vivax malaria in this region carried CYP2D6 alleles with an AS ≤1.25, suggesting the consideration for higher PQ doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.